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repeatedly measured up to 24 h using liquid chromatogra-
phy-tandem mass spectroscopy. MDMA significantly in-
creased the plasma concentrations of cortisol, corticoste-
rone, 11-dehydrocorticosterone, and 11-deoxycorticoste-
rone and also tended to moderately increase aldosterone 
levels compared with placebo. MDMA also increased the 
sum of cortisol + cortisone and the cortisol/cortisone ratio, 
consistent with an increase in glucocorticoid production. 
MDMA did not alter the levels of cortisone, DHEA, DHEAS, 
androstenedione, or testosterone. Methylphenidate did not 
affect any of the steroid concentrations, and it did not 
change the effects of MDMA on circulating steroids. In sum-
mary, the serotonin releaser MDMA has acute effects on cir-
culating steroids. These effects are not observed after stim-
ulation of the dopamine and norepinephrine systems with 
methylphenidate. The present findings support the view 
that serotonin rather than dopamine and norepinephrine 
mediates the acute pharmacologically induced stimulation 
of the hypothalamic-pituitary-adrenal axis in the absence of 
other stressors.  © 2014 S. Karger AG, Basel 
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 Abstract 
 3,4-Methylenedioxymethamphetamine (MDMA, ‘ecstasy’) 
and methylphenidate are widely used psychoactive sub-
stances. MDMA primarily enhances serotonergic neuro-
transmission, and methylphenidate increases dopamine 
but has no serotonergic effects. Both drugs also increase 
norepinephrine, resulting in sympathomimetic properties. 
Here we studied the effects of MDMA and methylphenidate 
on 24-hour plasma steroid profiles. 16 healthy subjects (8 
men, 8 women) were treated with single doses of MDMA 
(125 mg), methylphenidate (60 mg), MDMA + methylpheni-
date, and placebo on 4 separate days using a cross-over 
study design. Cortisol, cortisone, corticosterone, 11-dehy-
drocorticosterone, aldosterone, 11-deoxycorticosterone, 
dehydroepiandrosterone (DHEA), dehydroepiandrosterone 
sulfate (DHEAS), androstenedione, and testosterone were 
 Received: March 19, 2014 
 Accepted after Revision: May 26, 2014 
 Published online: June 5, 2014 
 Matthias E. Liechti 
 Division of Clinical Pharmacology and Toxicology 
 University Hospital Basel, Hebelstrasse 2 
 CH–4031 Basel (Switzerland) 
 E-Mail matthias.liechti   @   usb.ch
Alex Odermatt
Division of Molecular and Systems Toxicology
Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50
CH–4056 Basel (Switzerland)
E-Mail alex.odermatt   @   unibas.ch 
 © 2014 S. Karger AG, Basel
0028–3835/14/1001–0017$39.50/0 
 www.karger.com/nen 
 J. Seibert, C.M. Hysek, M.E. Liechti and A. Odermatt contributed 
equally to this work. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/1
1/
20
17
 2
:5
2:
41
 P
M
 Seibert/Hysek/Penno/Schmid/
Kratschmar/Liechti/Odermatt 
Neuroendocrinology 2014;100:17–25
DOI: 10.1159/000364879
18
 Introduction 
 Many recreational drugs activate the hypothalamic-
pituitary-adrenal (HPA) axis to release adrenocortico-
tropic hormone (ACTH) and corticosteroids  [1] . The 
neurochemical mechanisms involved in HPA axis acti-
vation depend on the particular drug and mostly involve 
corticotropin-releasing factor stimulation in the hypo-
thalamus  [1–3] . HPA axis activation by cocaine and am-
phetamine and its derivatives is thought to be mediated 
by increases in brain monoamines, including dopamine 
(DA), norepinephrine (NE), and serotonin (5-hydroxy-
tryptamine, 5-HT)  [1] . Few studies have examined 
which of these monoamines contribute the most to HPA 
axis activation in animals  [1] , and even less data are 
available for humans. For example, cocaine inhibits the 
uptake of all three monoamines (DA, NE, and 5-HT), 
and all three may be involved in cocaine-induced HPA 
axis activation. Dopaminergic and adrenergic receptor 
antagonists reduced the corticosterone response to co-
caine in rodents  [4–6] . Additionally, the blockade of 
5-HT receptors also decreased the ACTH response to 
cocaine in rats  [5] .
 3,4-Methylenedioxymethamphetamine (MDMA; ‘ec-
stasy’) primarily releases 5-HT in the brain via the sero-
tonin transporter (SERT) and NE via the NE transporter 
(NET)  [7] . Methylphenidate is an amphetamine deriva-
tive used for the treatment of attention-deficit/hyperac-
tivity disorder and misused as a cognitive enhancer and 
recreationally. In contrast to MDMA, methylphenidate 
only elevates the levels of DA and NE by inhibiting the 
DA transporter and NET  [8] . Thus, both MDMA and 
methylphenidate share an enhancing effect on NE neuro-
transmission, resulting in sympathomimetic and psycho-
stimulant effects  [9] , but they are otherwise indirect sero-
tonergic or dopaminergic agonists, making them phar-
macological tools to evaluate the role of 5-HT and DA as 
activators of the HPA axis.
 Several studies evaluated the stimulant effects of 
MDMA on the HPA axis in humans [for reviews, see  10, 
11] . Plasma cortisol has been shown to be increased after 
MDMA administration in many human laboratory 
studies  [12–15] and in recreational ecstasy users follow-
ing MDMA administration in a club setting  [16, 17] . 
Small laboratory studies also previously reported 
 MDMA-induced increases in ACTH  [18] and dehydro-
epiandrosterone (DHEA)  [12] . A trend toward an in-
crease in testosterone was also found in subjects who 
used MDMA at a dance club  [16] . However, the effects 
of MDMA on a wider range of corticosteroids have not 
yet been studied in humans. Therefore, we evaluated the 
acute effects of predominantly 5-HT activation using 
MDMA or predominantly DA activation using methyl-
phenidate or MDMA + methylphenidate on changes in 
the plasma concentration of a series of steroids over 24 h 
in healthy subjects. Specifically, we measured the plas-
ma levels of glucocorticoids (cortisol, cortisone, corti-
costerone, and 11-dehydrocorticosterone), mineralo-
corticoids (aldosterone and 11-deoxycorticosterone), 
and androgens (DHEA, DHEA sulfate (DHEAS), an-
drostenedione, and testosterone). Cortisol is the main 
active glucocorticoid and a major stress hormone. It is 
converted to the inactive metabolite cortisone. Corti-
costerone is also a potent activator of glucocorticoid and 
mineralocorticoid receptors, but it is present at 10- to 
20-times lower concentrations than cortisol in humans. 
11-Deoxycorticosterone is a precursor of corticosterone 
and aldosterone and exhibits mineralocorticoid activity 
 [19] . Mineralocorticoids increase renal sodium absorp-
tion and blood pressure. Androgens may modulate the 
addictive effects of drugs of abuse  [12, 20, 21] . We hy-
pothesized that methylphenidate and MDMA would 
differentially affect the plasma levels of these steroids 
based on their different pharmacological profiles.
 Methods 
 Study Design 
 The study used a double-blind, placebo-controlled, cross-over 
design with four experimental test sessions (placebo-placebo, 
methylphenidate-placebo, placebo-MDMA, and methylpheni-
date-MDMA) performed in counterbalanced order according to a 
Latin square randomization scheme. All of the subjects received all 
of the study treatments in a within-subjects study design. The 
washout periods between sessions were at least 10 days. The study 
was conducted in accordance with the Declaration of Helsinki and 
International Conference on Harmonization Guidelines in Good 
Clinical Practice and approved by the local Ethics Committee and 
Swiss Agency for Therapeutic Products (Swissmedic). The study 
was registered at ClinicalTrials.gov: http://clinicaltrials.gov/ct2/
show/NCT01465685. All of the subjects provided written in-
formed consent.
 Participants 
 Sixteen healthy subjects (8 men and 8 women; mean ± SD age 
24.8 ± 2.6 years) were recruited from the University of Basel cam-
pus. The exclusion criteria were acute or chronic physical illness, 
psychiatric disorders, smoking, and a lifetime history of using il-
licit drugs more than 5 times, with the exception of past cannabis 
use. The use of any illicit drugs, including cannabis, within the past 
2 months or during the study period was prohibited. We per-
formed urine drug tests at screening and before each test session 
using Triage ® 8 (Biosite, San Diego, Calif., USA). Female partici-
pants were investigated during the follicular phase of their men-
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strual cycle (days 2–14) to account for cyclic changes in the reac-
tivity to amphetamines. A detailed description of the participants 
has been previously published  [9] .
 Study Procedures 
 Methylphenidate (60 mg, Ritalin ® ; Novartis, Bern, Switzerland) 
or placebo was administered orally at 08: 00 h. MDMA (125 mg, 
racemic MDMA hydrochloride; Lipomed, Arlesheim, Switzerland) 
or placebo was administered orally at 09: 00 h. A standardized lunch 
was served at 12: 00 h, and the subjects were sent home at 18: 00 h. 
The day following each test session, the participants returned to the 
research ward at 09: 00 h for the collection of the 24-hour blood 
sample.  The subjects did not engage in any physical activity and 
were resting in hospital beds during the test session. Blood samples 
for the analysis of plasma steroid hormone levels (cortisol, corti-
sone, corticosterone, 11-dehydrocorticosterone, 11-deoxycortico-
sterone, aldosterone, DHEA, DHEA-S, androstenedione, and tes-
tosterone) were collected 1 h prior to MDMA or placebo adminis-
tration and 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, and 24 h 
following the administration of MDMA or placebo. The psychotro-
pic and autonomic effects of MDMA and methylphenidate from 
the present study have been presented elsewhere  [9] .
 Steroid Quantification 
 A detailed description of the materials, procedure, and 
 method  validation is included in the see online supplementary 
 material (for  all online suppl. material, see www.karger.com/
doi/10.1159/000364879). Briefly, plasma samples (1 ml) were 
mixed with 200 μl precipitation solution (0.8  M zinc sulfate in wa-
ter/methanol and deuterium-labeled aldosterone, cortisol, corti-
costerone, and testosterone as internal standards), diluted with 
water to 2 ml and centrifuged again. The supernatants were sub-
jected to Oasis HBL SPE cartridges for purification. The samples 
were reconstituted in 25 μl methanol. Steroids were separated and 
quantified by ultra-pressure liquid chromatography-tandem mass 
spectroscopy (UPLC-MS/MS) using an Agilent 1290 UPLC cou-
pled to an Agilent 6490 triple quadrupole MS equipped with an 
electrospray ionization source (Agilent Technologies, Basel, 
 Switzerland). The separation of analytes was achieved using a re-
verse-phase column (ACQUITY UPLC TM BEH C 18 , 1.7 μm, 2.1, 
150 mm; Waters, Wexford, Ireland). Mass Hunter software (Agi-
lent Technologies) was used for data acquisition and analysis. For 
method validation, see online supplementary material. 
 Statistical Analyses 
 Peak concentration (C max ) values were determined for all 
 repeated measures. Repeated-measures analyses of variance 
( ANOVAs) with the within-subject factors MDMA (MDMA vs. 
placebo) and methylphenidate (methylphenidate vs. placebo), fol-
lowed by the Tukey post hoc tests based on significant main effects 
of interactions in the ANOVA were used to assess differences in 
the effect of the different treatment conditions. Associations were 
assessed using Spearman’s rank correlations. One subject was ex-
cluded from the correlational analyses because of missing values. 
Because the effects of MDMA were similar regardless of whether 
MDMA was administered alone or combined with methylpheni-
date, the data were pooled for the correlational analyses (n = 30). 
The significance level was set to p = 0.05. The statistical analysis 
was performed using R project statistical packages (R Foundation 
for Statistical Computing, Vienna, Austria).
 Results 
 The peak levels of plasma steroid hormone concentra-
tions and statistics are shown in  table 1 . MDMA signifi-
cantly increased the plasma levels of the glucocorticoids 
cortisol, corticosterone, and 11-dehydrocorticosterone 
and mineralocorticoid 11-deoxycorticosterone compared 
with placebo ( fig. 1 a, c–e) but not the glucocorticoid cor-
tisone ( fig.  1 b). MDMA also significantly increased the 
sum of cortisol + cortisone and cortisol/cortisone ratio 
( table 1 ). The sum of corticosterone + 11-dehydrocortico-
sterone was also significantly elevated (data not shown), 
further supporting the increase in glucocorticoid produc-
tion. The levels of the mineralocorticoid aldosterone were 
increased by MDMA (significant main effect) but this ef-
fect was only significant for the MDMA + methylpheni-
date condition compared with placebo ( fig. 1 f). MDMA 
did not significantly alter the circulating levels of the an-
drogens DHEA, DHEAS, androstenedione, or testoster-
one ( fig. 2 a–e). For unknown reasons the absolute values 
obtained for DHEAS were lower than expected, allowing 
qualitative comparison only. Methylphenidate did not af-
fect any of the measured glucocorticoid, mineralocorti-
coid, or androgen hormones compared with placebo 
( fig. 1 ,  2 ). Administration of MDMA + methylphenidate 
led to similar hormonal responses compared with MDMA 
alone ( fig. 1 ,  2 ), with the exception of a more robust and 
significant increase in aldosterone. There were no interac-
tive effects of MDMA and methylphenidate on steroid 
levels. As expected, testosterone levels were lower in wom-
en than in men. No sex differences were observed in the 
effects of the drugs on steroid levels. However, significant 
positive correlations were found between the MDMA-in-
duced peak elevation of 11-deoxycorticosterone and aldo-
sterone and the peak increase in systolic blood pressure 
(R s  = 0.38 and 0.40, respectively, both p < 0.05, n = 30)  [9] . 
None of the steroid levels (peak or area under the concen-
tration-time curve changes from baseline) correlated with 
the simultaneously recorded psychotropic effects of 
MDMA including ‘good drug effects’, ‘drug liking’, ‘drug 
high’, ‘happy’, and ‘stimulated’ that have been reported 
previously  [9] . The time from MDMA administration to 
C max for cortisol, corticosterone, 11-dehydrocorticoster-
one, 11-deoxycorticosterone, and aldosterone was 2.1 ± 
0.8, 1.8 ± 0.6, 2.0 ± 0.6, 1.5 ± 0.5 h and 2.1 ± 1.5 h (mean ± 
SD), respectively. The time to C max for MDMA was 2.4 ± 
0.4 h  [9] . The MDMA-induced acute increases in circulat-
ing steroids generally disappeared within 6 h after drug 
administration. The plasma levels of cortisol, determined 
by UPLC-MS/MS (present findings) or radioimmunoas-
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say  [9] , at the 2 h time point after MDMA administration 
were significantly correlated across all measurements 
(R s  = 0.77, p < 0.001, respectively, n = 64).
 Discussion 
 The present study provides insights into the acute ef-
fects of two sympathomimetic drugs or pharmacological 
stressors on the plasma levels of a series of steroids in 
healthy humans. MDMA increased the plasma levels of 
the glucocorticoid cortisol. MDMA also increased the 
plasma levels of corticosterone and the inactive steroid 
11-dehydrocorticosterone, which is known to change in 
parallel with cortisol  [22] . Although circulating concen-
trations of corticosterone are lower than those of cortisol, 
a significantly increased ratio of corticosterone to cortisol 
was observed in the brain as a result of differential trans-
port by the P-glycoprotein at the blood-brain barrier  [23] . 
MDMA had no effect on the inactive cortisol metabolite 
cortisone, which is produced by 11β-hydroxysteroid de-
hydrogenase (11β-HSD) type 2, mainly in the kidney, and 
the reverse reaction is catalyzed by 11β-HSD1  [24] . Nota-
bly, MDMA increased both the sum of cortisol + cortisone 
levels and cortisol/cortisone ratio, suggesting an increase 
in HPA axis stimulation and possibly reduced or saturated 
11β-HSD2 enzyme function  [25] . A high cortisol/corti-
sone ratio has also been observed after acute ACTH ad-
ministration and in patients with chronic ACTH hyperse-
cretion  [25] . In contrast, a low cortisol/cortisone ratio 
characterizes adrenal insufficiency  [26] . MDMA also in-
creased the levels of the mineralocorticoids 11-deoxycor-
ticosterone and aldosterone, an effect that reached signif-
icance for the latter only when MDMA was co-adminis-
tered with methylphenidate. The mineralocorticoids, 
including aldosterone and 11-deoxycorticosterone, phys-
iologically increase renal sodium absorption and blood 
pressure. We observed a significant  association between 
MDMA-induced increases in mineralocorticoids and in-
creases in systolic blood pressure. However, MDMA does 
not alter plasma sodium levels or plasma osmolality as 
shown in a previous study  [27] . This finding would be well 
explained by the fact that MDMA also increases plasma 
arginine vasopressin  [27, 28] , which increases water reten-
tion and therefore has similar effects on blood pressure as 
aldosterone but opposite effects on plasma sodium levels. 
In fact, MDMA tended to increase urine osmolality  [27] . 
In the present study, MDMA did not affect the concentra-
tions of the androgens DHEA, DHEAS, androstenedione, 
or testosterone. Methylphenidate alone did not increase 
 Table 1.  Absolute peak plasma steroid concentrations and statistics
Placebo-
placebo
(mean ± SE)
Placebo-
MDMA
(mean ± SE)
Methylphenidate-
placebo
(mean ± SE)
Methylphenidate-
MDMA
(mean ± SE)
MDMA Methylphenidate Methylpheni date × 
MDMA
  F1,16 p value F1,16 p value F1,16 p value
Glucocorticoids
Cortisol, nM 463±53 770±45*** 556±54 765±43*** 43.47 <0.001 3.05 0.10 2.39 0.14
Cortisone, nM 36.7±1.8 40.9±2.7 43.4±3.0 42.6±2.2 0.34 0.57 3.65 0.08 1.39 0.26
Corticosterone, nM 8.4±1.5 29.7±2.4*** 12.8±2.4### 26.1±3.6*** 46.35 <0.001 0.05 0.82 2.54 0.13
11-Dehydrocorticosterone, nM 2.0±0.3 5.1±0.4*** 2.9±0.4### 5.2±0.5*** 45.49 <0.001 4.75 0.05 1.65 0.22
Cortisol + cortisone 499±52 796±45*** 582±54### 802±43*** 43.47 <0.001 3.05 0.10 1.46 0.25
Cortisol/cortisone ratio 15.8±1.7 24.8±1.5*** 16.6±1.5### 23.21±1.46*** 26.77 <0.001 0.29 0.60 1.24 0.28
Mineralocorticoids
Aldosterone, nM 0.16±0.04 0.25±0.06 0.17±0.04 0.33±0.11* 5.56 0.03 1.02 0.33 1.14 0.30
11-Deoxycorticosterone, nM 0.21±0.06 0.42±0.08** 0.26±0.07# 0.44±0.08*** 14.57 0.002 0.86 0.37 0.16 0.69
Androgens
DHEA, nM 24.7±6.6 24.6±3.5 19.7±2.4 23.7±3.4 0.69 0.42 0.95 0.35 0.27 0.61
DHEAS, nM 787±75 1.036±103 954±140 1,032±98 2.81 0.11 1.74 0.21 1.28 0.28
Androstenedione, nM 6.0±1.1 7.5±1.0 6.4±0.8 7.3±0.9 3.69 0.07 0.13 0.73 0.78 0.39
Testosterone in women, nM 0.59±0.25 0.55±0.14 0.45±0.19 0.57±0.10 0.07a 0.80 0.65a 0.45 0.45a 0.53
Testosterone in men, nM 11.8±4.4 13.0±3.9 14.0±4.3 13.0±4.0 0.00a 0.97 2.35a 0.17 3.03a 0.13
 Values are peak concentrations (mean ± SEM) of 16 subjects. * For p < 0.05, ** for p < 0.01, and *** for p < 0.001 compared to placebo-placebo. # For 
p < 0.05, and ### for p < 0.001 compared to placebo-MDMA (Tukey post hoc tests based on significant main effects in the ANOVAs).
a F1,7 (8 instead of 16 subjects).
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 Fig. 1.  a–f Effects of MDMA and methylphenidate on plasma con-
centration-time profiles of glucocorticoids and mineralocorti-
coids. The values are expressed as mean ± SEM in 16 subjects. 
MDMA was administered at t = 0 h. Methylphenidate was admin-
istered at t = –1 h. MDMA significantly increased the plasma con-
centrations of cortisol ( a ), corticosterone ( c ), 11-dehydrocortico-
sterone ( d ), and weak mineralocorticoid 11-deoxycorticosterone 
( e ) but not the non-bioactive glucocorticoid cortisone ( b ). MDMA 
also tended to moderately increase the plasma levels of the miner-
alocorticoid aldosterone ( f ). Similar changes in plasma steroid lev-
els were induced regardless of whether MDMA was administered 
alone or combined with methylphenidate ( a–f ). In contrast to 
MDMA, methylphenidate did not alter the plasma levels of any of 
the steroids ( a–f ). CYP = Cytochrome P450. 
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 Fig. 2. Effects of MDMA and methylphenidate on plasma concen-
tration-time profiles of androgens. The values are expressed as the 
mean ± SEM in 16 subjects (8 subjects for testosterone). MDMA 
was administered at t = 0 h. Methylphenidate was administered at 
t = –1 h. MDMA did not significantly alter the plasma concentra-
tions of DHEA ( a ), DHEAS ( b ), androstenedione ( c ), or testos-
terone in men ( d ) or women ( e ). Similar changes in plasma an-
drogen levels were induced regardless of whether MDMA was ad-
ministered alone or combined with methylphenidate ( a–e ). 
Similarly, methylphenidate did not alter the plasma levels of any 
of the androgens ( a–e ). 17β-HSD = 17β-Hydroxysteroid dehy-
drogenase. 
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the concentrations of any of the steroids measured. Co-
administration of MDMA + methylphenidate produced a 
similar hormonal response to MDMA alone.
 Several previous laboratory studies have documented 
similar and maximal 2-fold (50–100%) increases in plas-
ma cortisol levels in response to comparable doses of 
MDMA  [12–15] . In contrast, 2- to 8-fold increases in cor-
tisol levels were observed in dance clubbers who used 
MDMA while physically active  [16, 17, 29] . Moderate 
MDMA-induced elevations of DHEA were seen in a pre-
vious laboratory study  [12] . The effects of MDMA on all 
of the other steroids reported herein have not been previ-
ously described in a placebo-controlled setting. A non-
significant trend toward an increase in plasma testoster-
one levels has been reported in healthy subjects who used 
MDMA at a dance club  [16] . In contrast, we did not ob-
serve any effects of MDMA on testosterone levels in our 
placebo-controlled study.
 Methylphenidate at an oral dose of 60 mg did not affect 
steroid levels in the present study. Similarly, oral methyl-
phenidate at a dose of 20 mg did not alter plasma cortisol 
levels in healthy subjects  [30, 31] . In contrast, intravenous 
methylphenidate at doses of 10 mg (0.12–0.15 mg/kg) or 
0.3 mg/kg significantly increased cortisol levels in healthy 
subjects  [32] . Related catecholaminergic substances, such 
as amphetamine and methamphetamine, have also been 
shown to elevate cortisol levels in some studies  [33–36] 
but not others  [14] . A single dose of the NET inhibitor 
reboxetine also increased cortisol levels  [37] , particularly 
in subjects who scored high on subclinical depression 
 [38] . Chronic treatment with methylphenidate increased 
the levels of DHEA and DHEAS but not cortisol in chil-
dren with attention-deficit/hyperactivity disorder  [39] . 
There are several possible explanations why methylphe-
nidate at a relatively high single oral dose of 60 mg  [40, 
41] did not affect steroid levels in the present study. For 
example, cortisol levels are typically highest in the morn-
ing, which is when methylphenidate was administered in 
our study. In contrast, in studies that reported significant 
increases in cortisol, methylphenidate was administered 
in the evening, when cortisol levels are typically low  [32] . 
Additionally, physical activity may have enhanced the re-
sponse to stimulant drugs in some previous studies  [29] , 
whereas our subjects were resting. Finally, a significant 
response was observed with intravenous but not oral ad-
ministration, possibly because of faster changes associ-
ated with the mode of drug exposure.
 Pharmacologically, MDMA activates the 5-HT system, 
and methylphenidate does not  [7] . MDMA but not meth-
ylphenidate increased plasma prolactin levels  [9] , which is 
a clinical marker of serotonergic activity  [42] . The present 
study, therefore, indicates that 5-HT plays a crucial role in 
mediating activation of the HPA axis. In rats, the MDMA-
induced release of ACTH or corticosterone has been 
shown to involve 5-HT release and 5-HT 1 and 5-HT 2 re-
ceptor stimulation  [43, 44] . We previously showed that 
MDMA-induced increases in plasma cortisol in humans 
were blocked by the SERT/NET inhibitor duloxetine  [13] , 
which blocks the interaction of MDMA with the SERT 
and NET and the resulting MDMA-induced transporter-
mediated release of 5-HT and NE  [7] , but were not blocked 
by the NET inhibitor reboxetine  [13] , which only blocks 
the MDMA-induced release of NE  [45] .
 Additionally, MDMA and the 5-HT releaser meta-
chlorophenylpiperazine increased plasma cortisol levels, 
whereas amphetamine, which activates catecholamines 
more similarly to methylphenidate, did not  [14] . Selective 
activation of the 5-HT system by acute administration of 
the SERT inhibitor citalopram also increased plasma and 
salivary cortisol levels  [46] . Six-day treatment with citalo-
pram but not the NET inhibitor reboxetine also increased 
waking salivary cortisol levels  [47] . Finally, significant as-
sociations have been reported between polymorphisms in 
the genes that encode the SERT and HPA axis reactivity 
 [48] . Thus, these findings indicate a role for 5-HT in the 
mediation of MDMA-induced HPA axis stimulation in 
humans but little or no role for NE. Additionally, MDMA 
releases 5-HT from peripheral non-neuronal tissues di-
rectly into the blood plasma  [49] and 5-HT has been 
shown to directly stimulate aldosterone secretion by glo-
merulosa cells  [50] .
 One important issue is the clinical relevance of  MDMA’s 
effects on corticosteroids. Steroids are involved in a wide 
range of central and peripheral physiological functions re-
lated to mood, cognition, adaptation to stress, immune 
function, and others. In the context of recreational drug 
use, cortisol, DHEA, and testosterone may contribute to 
or modulate substance-induced acute psychotropic and 
reinforcing effects  [12, 20, 21] . For example, MDMA-in-
duced increases in plasma cortisol levels have previously 
been shown to correlate with subjective drug liking in re-
sponse to MDMA in a laboratory study  [12] . Stress-in-
duced increases in cortisol were also correlated with posi-
tive mood responses to amphetamine  [51] . Nonetheless, 
we found no associations between plasma steroid levels 
and any of the previously reported psychotropic effects of 
MDMA in the present study  [9] or in our previous work 
 [13] . It is possible that we missed a true association be-
cause of the small study size. It is also possible that the 
subjective and some endocrine responses were maximal 
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and therefore similar in most subjects (low between-sub-
ject variability). For example, such a lack of between-sub-
jects correlations has previously been documented for 
correlations between MDMA plasma levels and autonom-
ic effects  [52] . The pleasurable effects of amphetamine and 
methamphetamine in humans also did not change when 
cortisol levels were increased pharmacologically  [53] or 
lowered by metyrapone administration prior to metham-
phetamine administration  [33] . As noted above, MDMA-
induced elevations of mineralocorticoids may also con-
tribute to regulation of the hypertensive effects of MDMA. 
Corticosteroids may also facilitate the development of hy-
perthermia associated with amphetamines, a potentially 
fatal complication of recreational ecstasy use  [54, 55] . In 
rats, adrenalectomy or administration of a glucocorticoid 
receptor antagonist suppressed methamphetamine- and 
MDMA-induced increases in body temperature  [56–58] . 
Human data are lacking, but MDMA-induced elevations 
of steroids may contribute to the clinical toxicity of ec-
stasy  [16, 29] . Finally, repeated HPA axis stimulation by 
MDMA may contribute to chronic toxicity  [11, 17, 29] , 
including the deficits in neurocognitive function de-
scribed in heavy ecstasy users  [59] .
 The present study has several limitations. First, we used 
only single doses of the drugs. However, the selected dos-
es were high and produced pronounced and comparable 
sympathomimetic and drug-typical psychotropic effects 
 [9] . Second, we did not assess corticotropin-releasing fac-
tor or ACTH levels to describe the drugs’ effects on other 
mediators within the HPA axis. Instead, we provided the 
full profiles of ten steroids. Specifically, we included corti-
costerone, which is the biologically relevant glucocorti-
coid in rodents, the mineralocorticoid aldosterone, and 
androgens, which may play a role in mood regulation.
 In conclusion, the MDMA- but not methylphenidate-
induced effects on plasma steroids are consistent with a 
role for 5-HT in drug-induced HPA axis stimulation in 
the absence of other (psychosocial) stressors. Remaining 
to be investigated are whether and how the different ste-
roids contribute to the acute and chronic effects of these 
psychoactive drugs.
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